Article

Dr. Anne Chiang Named Executive Officer of SWOG

Anne Chiang, MD, PhD, has been appointed an Executive Officer of the Southwest Oncology Group Cancer Research Network.

Anne Chiang, MD, PhD

Anne Chiang, MD, PhD

New Haven, Conn. — Anne Chiang, MD, PhD, Associate Professor of Medicine (Medical Oncology), Chief Integration Officer at Yale Cancer Center and Deputy Chief Medical Officer of Smilow Cancer Network has been appointed an Executive Officer of the Southwest Oncology Group (SWOG) Cancer Research Network. Chiang will oversee the SWOG portfolio of clinical trials in lung and breast cancers.

“I’m thrilled about this addition to the leadership team,” said SWOG Chair Charles D. Blanke, MD, in an online announcement. “Anne is a gifted physician, successful researcher and a proven leader and she knows and supports SWOG. She has been an active member of the SWOG lung committee.”

SWOG is a major part of the cancer research infrastructure in the United States and the world. SWOG has members in 47 states and six other countries as part of the National Cancer Institute's National Clinical Trials Network, or NCTN.

“I’m honored to be a part of the SWOG leadership team,” said Chiang. “Cooperative group research is so critical to providing access to quality, innovative cancer care to all patients in their own communities. We’ve been committed to this philosophy at Yale Cancer Center and Smilow Cancer Hospital and I look forward to bringing this knowledge to my position at SWOG.”

“Our lung and breast committees are among SWOG’s largest and most productive, and trials coming from these groups have changed the standard of care dozens of times,” said Blanke. “I am grateful for Anne’s interest and her future efforts on behalf of our lung and breast cancer investigators.”

Chiang starts in her new position May 1st.

About Yale Cancer Center and Smilow Cancer Hospital

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Related Videos
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma